<DOC>
	<DOC>NCT01457807</DOC>
	<brief_summary>To evaluate the pharmacokinetics of AZD3241 following multiple administration of 2 new, different extended release formulations of tablets of AZD3241 (300 mg), in relation to the 100 mg extended release tablet used in a previous study and potential food interaction. The safety and tolerability of AZD 3241 will also be investigated as a secondary objective. In addition to these a number of exploratory objectives will be investigated with blood sampling.</brief_summary>
	<brief_title>To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers</brief_title>
	<detailed_description>A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) after Administration of Multiple Doses in Healthy Male and Female Volunteers</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Provision of signed and dated, written informed consent prior to any study specific procedures Healthy male or female volunteers aged 30 to 65 years, inclusive, with suitable veins for cannulation or repeated venepuncture Female volunteers must have a negative pregnancy test at Screening and on admission to the CPU, must not be lactating and must be of non childbearing potential, confirmed at Screening Male volunteers must be willing to use barrier contraception ie, condoms, from the first day of dose administration until 3 months after the last dose of the IP Volunteers must have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD3241 Orthostatic hypotension defined as 25 mmHg decrease in systolic and/or 15 mmHg decrease in diastolic BP as measured at enrolment and/or randomisation History of intolerance or hypersensitivity to mannitol Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF)&gt;450 ms or shortened QTcF&lt;340 ms or a family history of long QT syndrome Abnormal vital signs, after 10 minutes of rest in supine position, defined as any of the following:Systolic BP&gt;140 mmHg., Diastolic BP&gt;90 mmHg., Heart rate&lt;40 or &gt;85 beats per minute.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Parkinson's disease</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>biomarkers</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>extended release formulation</keyword>
</DOC>